Abstract 646P
Background
Creatine Kinase B (CKB) was identified as a driver of RASm mCRC. CKB generates ATP from phosphocreatine (PCr), which is imported by SLC6A8. Ompenaclid depletes PCr and ATP resulting in tumor cell apoptosis. In a phase 1a study, ompenaclid monotherapy showed objective anti-tumor activity in RASm mCRC without dose-limiting toxicities (DLTs).
Methods
Objectives of this ongoing phase 1b/2 study are evaluation of safety, PK/PD and efficacy of ompenaclid + FOLFIRI/BEV in 2L mCRC. Eligible pts had disease progression after a 1L oxaliplatin-containing regimen.
Results
Enrollment as of 28Apr2023, 35 pts (22 KRASm, 3 NRASm, 10 RAS-wt) in the Dose Escalation/Expansion cohorts receiving 2400mg BID (n=14) or 3000mg BID (n=21); all pts received FOLFIRI/BEV. No DLTs were observed in Dose Escalation and a MTD was not reached. Across safety-evaluable pts (n=33), the most common treatment emergent AEs Gr≤2 were nausea (50%), diarrhea (44%); Gr≥3 were neutropenia (15%), abdominal pain (11%), diarrhea (11%), fatigue (11%). The AE profile is similar to FOLFIRI/BEV alone, demonstrating good combinability. At both ompenaclid doses, systemic exposure was comparable and resulted in up to a 48X increase in urine creatine, suggesting robust target inhibition. The ORR in 17 RASm and 10 RAS-wt evaluable pts was 41% (6 confirmed PRs, 1 unconfirmed PR) and 20% (2 unconfirmed PRs), respectively. Five RASm pts are pending 1st scan and not yet evaluable. PRs were observed in pts with diverse KRASm (G13D [2 pts], G12V [2 pts], G12D, G12S and pG10dup). For RASm pts, mPFS was 11.8M and mOS was 19.1M, and for RAS-wt pts, mPFS was 7.5M and mOS was 14.5M.
Conclusions
At the evaluated dose levels, ompenaclid + FOLFIRI/BEV was well tolerated and induced potent inhibition of the target SLC6A8. Encouraging efficacy was observed in pts with RASm mCRC, with a response rate exceeding that expected with SOC. This preferential RASm activity is consistent with preclinical and phase 1a data. There is a high unmet need for a safe and combinable oral pan-RASm therapy in mCRC. Recruitment of RASm pts continues and a randomized controlled trial in 2L RASm mCRC is planned.
Clinical trial identification
NCT03597581.
Editorial acknowledgement
Lesley Skingley, Bexon Clinical Consulting.
Legal entity responsible for the study
Inspirna, Inc.
Funding
Inspirna, Inc.
Disclosure
D.R. Spigel: Financial Interests, Institutional, Other, Consulting: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Curio Science, EMD Serono, Evidera, Exelixis, Genentech/Roche, GSK, Intellisphere, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Mirati Therapeutics, Molecular Templates, Monte Rosa Therapeutics, Novartis, Pfizer, Puma Biotechnology, Regeneron, Sanofi-Aventis; Financial Interests, Institutional, Research Grant, Serve as PI: Amgen, Aeglea Biotherapeutics, Agios, Bayer, Arrys Therapeutics, Astellas, AstraZeneca, BeiGene, BIND Therapeutics, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celldex Therapeutics, Clovis, Daiichi Sankyo, Eisai, Lilly, EMD Serono, Genentech/Roche, G1 Therapeutics, Gilead Sciences, ImClone Systems, GSK, GRAIL, Hutchinson MediPharma, Ipsen, Janssen, Loxo, MacroGenics, MedImmune, Merck, Nektar, PTC Therapeutics, Neon Therapeutics, Novartis, Novocure, Rgenix, SeaGen, Taiho Oncology, Tarveda, Verastem, Tizona Therapeutics, Transgene, UT Southwestern, Arcus Biosciences, Oncologie, Molecular Template, Cyteir Therapeutics, BioNTech, Apollomics, Pure Tech Health, Elevation Oncology, Repare Therapeutics, Razor Genomics, Denovo Biopharma, Erasca, Kronos Bio, Zai Laboratory, Faeth Therapeutics, Ascendis Pharma, Lyell Immunopharma, Synthekine, Shenzhen Chipscreen Biosciences. M. Fakih: Financial Interests, Personal, Advisory Role: AstraZeneca, Bayer Corporation, Bristol Myers Squibb, Eisai Oncology, Entos, Merck, Roche/Genentech; Financial Interests, Personal, Advisory Board: Mirati, Nouscom; Financial Interests, Institutional, Research Grant: Genentech, Verastem. A.S. Paulson: Financial Interests, Personal, Invited Speaker, Medical education, non-branded, industry sponsored: Ideo Oncology; Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, Eisai, Ipsen, Incyte, Exelixis, AAA, Pfizer, QED, Lilly, Mirati, Hutchinson, Astellas; Financial Interests, Personal, Stocks/Shares: Alexion, Actinium, Aptose; Financial Interests, Invited Speaker: Ipsen, Hutchinson, Bristol Myers Squibb, Exelixis, Hutchinson med, Taiho, Lilly, AstraZeneca, Incyte, Seattle Genetics, Deciphera, Tempus, Zentalis, G1 therapeutics, Merck, Camurus, Novartis, Surface, Relay Therapeutics; Financial Interests, Institutional, Invited Speaker: Mirati, Bayer. R. Wasserman: Financial Interests, Personal, Advisory Board: Secotral Asset Management, Sixty Degree; Financial Interests, Personal, Officer: Inspirna; Financial Interests, Personal, Stocks/Shares: Inspirna, Sectoral Asset Management, Sixty Degree, Northern Biologics, Thatch Health; Financial Interests, Personal, Invited Speaker: Inspirna; Financial Interests, Personal, Royalties: Northern Biologics. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11